{'fraction_non_alphanumeric': 0.030229746070133012, 'fraction_numerical': 0.013301088270858524, 'mean_word_length': 5.369230769230769, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Eosinophil Development and Bone Marrow and Tissue Eosinophils in Atopic Asthma

Background: Eosinophils develop from bone marrow (BM) progenitors, and interleukin–5 (IL–5) and eotaxin may act in expansion and mobilisation of BM eosinophils in asthma. Methods: We have examined phenotypic changes as CD34+ cells develop to the eosinophil lineage in vitro, and have evaluated BM eosinophils from asthmatic and control subjects for expression of the eotaxin receptor, CCR3. Results: Acquisition of receptors for IL–5 and CCR3 was an early event in eosinophil development. There were increased CD34+ cells, and mature and immature CCR3+ eosinophils in BM from asthmatics. Conclusion: These data suggest that IL–5 may act early in eosinophil development, and that eotaxin has the capacity to mobilise a BM eosinophil pool in asthma.